Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 675K | 951K | 0 |
| Gross Profit | 0 | 0 | 675K | 951K | 0 |
| Operating Income | -30M | -32M | -21M | -18M | -9M |
| EBITDA | -26M | -36M | -30M | -18M | -9M |
| Net Income | -27M | -37M | -31M | -18M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$6.85
-2.84% today
1Y Change
+2.25%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Unicycive Therapeutics, Inc. (UNCY) is a Healthcare stock with a market cap of $160.00M and listed on NASDAQ. The stock last traded around $6.85 and up 2.3% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +70.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +70.2%, free cash flow -9.4% with operating margin 0.0% and ROIC -97.4%. Stock Foundry combines UNCY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UNCY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UNCY Max Drawdown
-47.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UNCY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$10.0M
+44.5% YoY
Free Cash Flow
-$5.8M
+63.0% YoY
Revenue Growth
+0.0%
EPS Growth
+70.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 675K | 951K | 0 |
| Gross Profit | 0 | 0 | 675K | 951K | 0 |
| Operating Income | -30M | -32M | -21M | -18M | -9M |
| EBITDA | -26M | -36M | -30M | -18M | -9M |
| Net Income | -27M | -37M | -31M | -18M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 29M | 26M | 10M | 455K | 17M |
| Total Assets | 49M | 32M | 14M | 3M | 19M |
| Total Liabilities | 19M | 24M | 18M | 3M | 2M |
| Shareholder Equity | 30M | 7M | -4M | -466K | 16M |
| Total Debt | 117K | 773K | 811K | 201K | 335K |
| Net Debt | -29M | -25M | -9M | -254K | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+63.2% YoY
Capital Expenditures
29K
-1350.0% YoY
Free Cash Flow
6M
+63.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-111.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.